Key terms

About KPRX

Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest KPRX news

Mar 28 7:30am ET Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Kiora Pharmaceuticals (KPRX) and Actinium Pharmaceuticals (ATNM) by TipRanks Feb 28 4:52pm ET Kiora Pharmaceuticals files to sell 76.53M shares of common stock for holders by TipRanks Feb 12 5:33pm ET Kiora Pharmaceuticals Unveils Updated Investor Presentation by TipRanks Feb 09 6:16am ET Kiora Pharmaceuticals: Strong Buy Rating on Strategic Partnership and Promising Trial Results by TipRanks Feb 09 6:13am ET Kiora Pharmaceuticals price target lowered to $2 from $3.50 at H.C. Wainwright by TipRanks Feb 07 7:57am ET Kiora Pharmaceuticals (KPRX) Receives a Buy from Maxim Group by TipRanks Jan 31 5:45pm ET Kiora Pharmaceuticals Inc trading resumes by TipRanks Jan 31 5:10pm ET Kiora Pharmaceuticals Inc trading halted, news pending by TipRanks
Apr 11 7:00am ET Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study by Newsfile Apr 05 7:00am ET Kiora Pharmaceuticals to Present at Upcoming Investor Conferences by Newsfile Mar 28 6:45am ET Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting by Newsfile Mar 25 7:00am ET Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases by Newsfile Mar 08 2:00am ET Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye by Newsfile

KPRX Financials

1-year income & revenue

Key terms

KPRX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

KPRX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Student demonstrators occupy the pro-Palestinian "Gaza Solidarity Encampment" on the West Lawn of Columbia University on April 24, 2024 in New York City.
Michael M. Santiago/Getty Images
What the pro-Palestinian protesters on college campuses actually want
People walk by the New York Stock Exchange (NYSE) on March 20, 2024 in New York City. The Dow was up slightly in late morning trading as traders analyze the Federal Reserve's latest decision on interest rates.
Spencer Platt/Getty Images
Stagflation fears just hit Wall Street. Now for the next crucial report on prices
Meta headquarters pictured on February 02, 2023 in Menlo Park, California.
Justin Sullivan/Getty Images
Meta’s stock plunges 15% on ‘aggressive’ AI spending plans
GettyImages-1159438448 copy.jpg
Lyndon Stratford/iStockphoto/Getty Images
Americans are falling behind on their payments